CD274 and hepatocellular carcinoma: Combination therapy with the anti–programmed death-ligand 1 (anti-PD-L1) antibody atezolizumab and the anti–vascular endothelial growth factor-A (anti-VEGF-A) antibody bevacizumab (Atezolizumab/Bevacizumab) has commonly been used as first-line treatment for advanced hepatocellular carcinoma (HCC).